Mechanism of tumor-targeted delivery of macromolecular drugs, including the EPR effect in solid tumor and clinical overview of the prototype polymeric drug SMANCS - PubMed (original) (raw)
Review
Mechanism of tumor-targeted delivery of macromolecular drugs, including the EPR effect in solid tumor and clinical overview of the prototype polymeric drug SMANCS
H Maeda et al. J Control Release. 2001.
Abstract
This review article describes three aspects of polymeric drugs. The general mechanism of the EPR (enhanced permeability and retention) effect and factors involved in the effect are discussed, in view of the advantages of macromolecular therapeutics for cancer treatment, which are based on the highly selective EPR-related delivery of drug to tumor. Also described are advantages of more general water-soluble polymeric drugs as primary anticancer agents, using SMANCS as an example. Last, SMANCS/Lipiodol is discussed with reference to the type of formulation for arterial injection with most pronounced tumor selective delivery, as well as its advantages, precautions, and side effects from the clinical standpoint.
Similar articles
- [Recent advances in research on SMANCS].
Maeda H. Maeda H. Gan To Kagaku Ryoho. 1998 Feb;25 Suppl 1:1-9. Gan To Kagaku Ryoho. 1998. PMID: 9512680 Review. Japanese. - Factors and mechanism of "EPR" effect and the enhanced antitumor effects of macromolecular drugs including SMANCS.
Fang J, Sawa T, Maeda H. Fang J, et al. Adv Exp Med Biol. 2003;519:29-49. doi: 10.1007/0-306-47932-X_2. Adv Exp Med Biol. 2003. PMID: 12675206 Review. - SMANCS and polymer-conjugated macromolecular drugs: advantages in cancer chemotherapy.
Maeda H. Maeda H. Adv Drug Deliv Rev. 2001 Mar 1;46(1-3):169-85. doi: 10.1016/s0169-409x(00)00134-4. Adv Drug Deliv Rev. 2001. PMID: 11259839 - [SMANCS/lipiodol].
Maeda H. Maeda H. Gan To Kagaku Ryoho. 1994 May;21(6):907-13. Gan To Kagaku Ryoho. 1994. PMID: 8185354 Review. Japanese. - Intracavitary administration: pharmacokinetic advantages of macromolecular anticancer agents against peritoneal and pleural carcinomatoses.
Kimura M, Konno T, Miyamoto Y, Kojima Y, Maeda H. Kimura M, et al. Anticancer Res. 1998 Jul-Aug;18(4A):2547-50. Anticancer Res. 1998. PMID: 9703908
Cited by
- Targeted Drug Delivery Strategies for the Treatment of Hepatocellular Carcinoma.
Liu Y, Wu Y, Li Z, Wan D, Pan J. Liu Y, et al. Molecules. 2024 Sep 16;29(18):4405. doi: 10.3390/molecules29184405. Molecules. 2024. PMID: 39339402 Free PMC article. Review. - Microfluidic technologies for lipid vesicle generation.
Cheng Y, Hay CD, Mahuttanatan SM, Hindley JW, Ces O, Elani Y. Cheng Y, et al. Lab Chip. 2024 Oct 9;24(20):4679-4716. doi: 10.1039/d4lc00380b. Lab Chip. 2024. PMID: 39323383 Free PMC article. Review. - Advancing Breast Cancer Therapeutics: Targeted Gene Delivery Systems Unveiling the Potential of Estrogen Receptor-Targeting Ligands.
Lee JR, Kim YM, Kim EJ, Jang MK, Park SC. Lee JR, et al. Biomater Res. 2024 Sep 24;28:0087. doi: 10.34133/bmr.0087. eCollection 2024. Biomater Res. 2024. PMID: 39319107 Free PMC article. - Dynemicin A Derivatives as Potential Cancer Chemotherapeutics by Mutasynthesis.
Pal P, Alley JR, Cohen DR, Townsend CA. Pal P, et al. Helv Chim Acta. 2023 Dec;106(12):e202300123. doi: 10.1002/hlca.202300123. Epub 2023 Oct 21. Helv Chim Acta. 2023. PMID: 39308597 Free PMC article. - Recent updates in applications of nanomedicine for the treatment of hepatic fibrosis.
Setyawati DR, Sekaringtyas FC, Pratiwi RD, Rosyidah A, Azhar R, Gustini N, Syahputra G, Rosidah I, Mardliyati E, Tarwadi, El Muttaqien S. Setyawati DR, et al. Beilstein J Nanotechnol. 2024 Aug 23;15:1105-1116. doi: 10.3762/bjnano.15.89. eCollection 2024. Beilstein J Nanotechnol. 2024. PMID: 39188757 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources